Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Factors Affecting Soluble Mesothelin Related Protein Levels In An Asbestos-exposed Population

Eun-Kee Park, P. Thomas, J. Creaney, A. Johnson, B. Robinson, D. Yates
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Background: Soluble mesothelin-related protein (SMRP) is increased in the sera of patients with malignant mesothelioma (MM), and has been suggested as a diagnostic tool for MM in an asbestos exposed population. However, factors affecting SMRP concentrations in normal subjects and those with other asbestos related disorders have not been investigated in any large population based study. Methods: Five hundred and thirty-eight subjects with a history of asbestos exposure were studied. Age, height, weight, body mass index (BMI), serum creatinine and glucose, estimated glomerular filtration rate (eGFR) and lung function were compared with SMRP concentrations. Results: The mean age [± standard deviation (SD)] of participants was 66.9 (±10.1) years, and mean (±SD) serum SMRP concentration was 0.91 (±0.67) nmol/L. SMRP values were inversely associated with weight (Pearson r=–0.1254, p=0.0036), BMI (Pearson r=–0.1594, p=0.0002), blood glucose (Pearson r=–0.1515, p=0.0004), single-breath carbon monoxide diffusing capacity (DLco) % predicted (Pearson r=–0.1847, p<0.0001), eGFR (Pearson r=–0.2835, p<0.0001) and single-breath carbon monoxide diffusing capacity per unit alveolar volume (DLco/VA)% predicted (Pearson r=–0.1872, p<0.0001) but were positively associated with age (Pearson r=0.2315, p<0.0001) and creatinine (Pearson r=0.3833, p<0.0001). Conclusions: This study has shown that demographic variables, physiological factors and lung function are associated with serum SMRP concentrations. Confounding factors should be considered when interpreting serum SMRP. Clin Chem Lab Med 2010;48:869–74.
This paper references
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1515/CCLM.2007.112
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
F. di Serio (2007)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.
J. Cotes (1993)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.3816/CLC.2004.N.008
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
Derlis Martino (2004)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1016/J.HUMPATH.2003.11.013
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
10.1002/(SICI)1097-0274(200002)37:2<159::AID-AJIM1>3.0.CO;2-0
Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain.
A. Agudo (2000)
10.1373/clinchem.2008.121913
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
10.1136/oem.2008.039347
Occupational exposure to asbestos in New South Wales, Australia (1970–1989): development of an asbestos task exposure matrix
Rebecca A Hyland (2010)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.5271/SJWEH.1145
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
Rebecca A Hyland (2007)
10.5694/j.1326-5377.2009.tb02321.x
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin‐related protein and positron emission tomography
E. O'Lone (2009)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1016/J.THORSURG.2004.06.011
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
10.1164/ajrccm.152.3.7663792
Standardization of Spirometry, 1994 Update. American Thoracic Society.
C. Irvin (1995)
10.1136/oem.56.1.51
Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.
D. Howel (1999)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
Fujirebio Mesomark Assay. Humanitarian Device Exemption Number H060004, Document number 07M-0038
US FDA (2007)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1183/09041950.041s1693
Standardization of the measurement of transfer factor (diffusing capacity)
J. Cotes (1993)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Fujirebio Mesomark Assay. Humanitarian Device Exemption Number H060004, Document number 07M-0038
US FDA (2007)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1164/AJRCCM/138.4.1084
Single breath carbon monoxide diffusing capacity (transfer factor)
D. Johns (1988)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)



This paper is referenced by
10.1007/s00420-013-0853-1
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
M. K. Felten (2013)
10.4155/bio.15.53
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.
Clementina A. Mesaros (2015)
10.1016/j.cllc.2011.12.004
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.
K. Hollevoet (2012)
10.7150/ijms.23939
Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population
G. Aguilar‐Madrid (2018)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.5507/bp.2014.014
Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure.
K. Vyskočilová (2015)
10.1136/oemed-2016-104024
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals
C. De Santi (2017)
10.1016/j.lungcan.2011.01.011
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
10.1007/s12032-012-0422-6
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1097/JTO.0b013e3181e392d7
Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma
J. Creaney (2010)
10.1186/s12885-017-3375-5
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
10.1007/978-3-319-53560-9_12
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
10.1007/s12199-015-0477-z
Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population
M. Yu (2015)
10.1007/978-3-030-53908-5_6
Malignant-Primary (MAL-P) (Mesothelioma)
C. W. Michael (2020)
10.5507/bp.2014.015
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
P. Jakubec (2015)
10.5301/JBM.2011.8332
Two Novel Polymorphisms in 5' Flanking Region of the Mesothelin Gene are Associated with Soluble Mesothelin-Related Peptide (SMRP) Levels
A. Cristaudo (2011)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
Chapter 12 Biomarkers of Response to Asbestos Exposure
Blair ()
10.3389/fonc.2019.00740
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
10.5491/SHAW.2012.3.1.17
Association of Biomarker Levels with Severity of Asbestos-Related Diseases
E. Park (2012)
10.1007/978-3-030-53908-5
The International System for Serous Fluid Cytopathology
A. Chandra (2020)
10.1158/1055-9965.EPI-20-0083
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
H. Pass (2020)
Semantic Scholar Logo Some data provided by SemanticScholar